UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On May 6, 2024, the Company issued a press release (the “Press Release”) announcing its financial results for the first quarter ended March 31, 2024. A copy of the Press Release is attached as Exhibit 99.1 to this current report on Form 8-K.
The information under Item 2.02 in this current report on Form 8-K and the related information in the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
(d) Exhibits
| Exhibit Number | Description | |
| 99.1 | Press Release dated May 6, 2024 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Shockwave Medical, Inc. | ||
| Date: May 6, 2024 | By: | /s/ Renee Gaeta |
| Renee Gaeta | ||
| Chief Financial Officer | ||
EXHIBIT 99.1
Shockwave Medical Reports First Quarter 2024 Financial Results
SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024.
“The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. “Our team is looking forward to continuing our mission as part of Johnson & Johnson and to working together to bring our life-changing therapies to even more patients across the globe.”
First Quarter 2024 Financial Results
Revenue for the first quarter ended March 31, 2024, was $218.8 million, a 36% increase from $161.1 million in the same period of 2023. The growth in revenue was primarily driven by increased adoption of Shockwave products in both the United States and internationally.
Gross profit for the first quarter of 2024 was $190.6 million compared to $140.0 million for the first quarter of 2023. Gross margin percentage was 87% for the three months ended March 31, 2024, consistent with gross margin for the three months ended March 31, 2023.
Total operating expenses for the first quarter of 2024 were $148.2 million, a 48% increase from $100.2 million in the first quarter of 2023. The increase was primarily driven by sales force expansion and higher headcount to support the growth of the business.
Net income for the first quarter of 2024 was $55.3 million, compared to net income of $39.1 million in the same period of 2023. Basic and diluted net income per share for the first quarter of 2024 was $1.48 and $1.44, respectively.
Adjusted EBITDA improved by approximately 19% to $68.5 million, in the first quarter of 2024, compared to adjusted EBITDA of $57.5 million in the first quarter of 2023. Adjusted EBITDA is a non-GAAP measure.
Cash, cash equivalents and short-term investments totaled $1,029.2 million as of March 31, 2024.
2024 Financial Guidance
Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical is withdrawing its full year 2024 guidance, previously issued on February 15, 2024.
Conference Call
Given the proposed acquisition of Shockwave Medical by Johnson & Johnson (NYSE: JNJ), Shockwave Medical will not be hosting the previously scheduled earnings conference call today.
About Shockwave Medical, Inc.
Shockwave Medical is a leader in the development and commercialization of innovative products that are transforming the treatment of cardiovascular disease. Its first-of-its-kind Intravascular Lithotripsy (IVL) technology has transformed the treatment of atherosclerotic cardiovascular disease by safely using sonic pressure waves to disrupt challenging calcified plaque, resulting in significantly improved patient outcomes. Shockwave Medical has also recently acquired the Reducer, which is under clinical investigation in the United States and is CE Marked in the European Union and the United Kingdom. By redistributing blood flow within the heart, the Reducer is designed to provide relief to the millions of patients worldwide suffering from refractory angina. Learn more at www.shockwavemedical.com.
Forward-Looking Statements
This press release contains statements relating to our expectations, projections, beliefs, and prospects, which are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue,” and similar expressions, and the negative of these terms. Forward-looking statements in this press release include, but are not limited to, statements regarding our pending acquisition by Johnson & Johnson, our business strategy and plans, our objectives for future operations and financial performance and other matters. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware.
If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Risks and uncertainties include, but are not limited to: the risk that the closing conditions for the pending acquisition will not be satisfied, including the risk that clearance under the Hart-Scott-Rodino Antitrust Improvements Act or other applicable antitrust laws will not be obtained; uncertainty as to the percentage of our stockholders that will vote to approve the proposed transaction; the possibility that the transaction will not be completed in the expected timeframe or at all; potential adverse effects to our business or the business of Johnson & Johnson during the pendency of the transaction, such as employee departures or distraction of management from business operations; the risk of stockholder litigation relating to the transaction, including resulting expense or delay; the potential that the expected benefits and opportunities of the acquisition, if completed, may not be realized or may take longer to realize than expected; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment. These factors, as well as others, are discussed in our filings with the Securities and Exchange Commission (SEC), including in the sections titled “Risk Factors” in our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, and in our other reports filed with the SEC. Except to the extent required by law, we do not undertake to update any of these forward-looking statements after the date hereof to conform these statements to actual results or revised expectations.
Use of Non-GAAP Financial Measures
This press release contains supplemental financial information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP), including references to adjusted EBITDA, a non-GAAP financial measure that excludes from net income the effects of income tax (benefit) provision, other (expense) income, net, interest expense, interest income, income (loss) from equity method investment, depreciation and amortization, and stock-based compensation. We believe the presentation of adjusted EBITDA is useful as it provides visibility to our underlying continuing operating performance by excluding the impact of certain items that are non-cash in nature or not related to our core business operations.
Our definition of adjusted EBITDA may differ from similarly titled measures used by others. Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease our reported results of operations, management strongly encourages investors to review, when they become available, our consolidated financial statements and publicly filed reports in their entirety. A reconciliation of adjusted EBITDA to net income has been provided in the financial statement tables included in this press release, and investors are encouraged to review the reconciliation.
Media Contact:
Scott Shadiow
+1.317.432.9210
sshadiow@shockwavemedical.com
Investor Contact:
Debbie Kaster
dkaster@shockwavemedical.com
| SHOCKWAVE MEDICAL, INC. | |||||||||||
| Balance Sheet Data | |||||||||||
| (in thousands) | |||||||||||
| March 31, 2024 | December 31, 2023 | ||||||||||
| (Unaudited) | |||||||||||
| ASSETS | |||||||||||
| CURRENT ASSETS: | |||||||||||
| Cash and cash equivalents | $ | 281,674 | $ | 328,422 | |||||||
| Short-term investments | 747,559 | 662,132 | |||||||||
| Accounts receivable, net | 124,440 | 114,552 | |||||||||
| Inventory | 111,215 | 107,587 | |||||||||
| Prepaid expenses and other current assets | 10,462 | 12,567 | |||||||||
| Total current assets | 1,275,350 | 1,225,260 | |||||||||
| Operating lease right-of-use assets | 34,919 | 29,707 | |||||||||
| Property and equipment, net | 78,693 | 68,923 | |||||||||
| Equity method investment | 2,356 | 1,643 | |||||||||
| Intangible assets, net | 91,960 | 92,857 | |||||||||
| Goodwill | 39,568 | 39,568 | |||||||||
| Deferred tax assets | 111,900 | 99,169 | |||||||||
| Other assets | 9,001 | 9,436 | |||||||||
| TOTAL ASSETS | $ | 1,643,747 | $ | 1,566,563 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| CURRENT LIABILITIES: | |||||||||||
| Accounts payable | $ | 9,843 | $ | 8,868 | |||||||
| Accrued liabilities | 78,838 | 91,696 | |||||||||
| Lease liability, current portion | 3,653 | 3,641 | |||||||||
| Total current liabilities | 92,334 | 104,205 | |||||||||
| Lease liability, noncurrent portion | 40,336 | 35,103 | |||||||||
| Convertible debt, noncurrent portion | 732,810 | 731,863 | |||||||||
| Related party contract liability, noncurrent portion | 12,273 | 12,273 | |||||||||
| Deferred tax liabilities | 3,609 | 3,609 | |||||||||
| Long-term income tax liability | 2,969 | 1,526 | |||||||||
| Other liabilities | 7,659 | 9,307 | |||||||||
| TOTAL LIABILITIES | 891,990 | 897,886 | |||||||||
| STOCKHOLDERS’ EQUITY: | |||||||||||
| Common stock | 38 | 37 | |||||||||
| Additional paid-in capital | 586,017 | 557,882 | |||||||||
| Accumulated other comprehensive (loss) income | (109 | ) | 293 | ||||||||
| Retained earnings | 165,811 | 110,465 | |||||||||
| TOTAL STOCKHOLDERS’ EQUITY | 751,757 | 668,677 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 1,643,747 | $ | 1,566,563 | |||||||
| SHOCKWAVE MEDICAL, INC. | |||||||||
| Statement of Operations Data | |||||||||
| (Unaudited) | |||||||||
| (in thousands, except share and per share data) | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2024 | 2023 | ||||||||
| Revenue: | |||||||||
| Product revenue | $ | 218,805 | $ | 161,066 | |||||
| Cost of revenue: | |||||||||
| Cost of product revenue | 28,207 | 21,066 | |||||||
| Gross profit | 190,598 | 140,000 | |||||||
| Operating expenses: | |||||||||
| Research and development | 44,466 | 26,971 | |||||||
| Sales and marketing | 74,492 | 54,011 | |||||||
| General and administrative | 29,233 | 19,204 | |||||||
| Total operating expenses | 148,191 | 100,186 | |||||||
| Income from operations | 42,407 | 39,814 | |||||||
| Income (loss) from equity method investment | 713 | (823 | ) | ||||||
| Interest income | 12,318 | 1,740 | |||||||
| Interest expense | (2,943 | ) | (636 | ) | |||||
| Other (expense) income, net | (2,496 | ) | 642 | ||||||
| Net income before taxes | 49,999 | 40,737 | |||||||
| Income tax (benefit) provision | (5,347 | ) | 1,612 | ||||||
| Net income | $ | 55,346 | $ | 39,125 | |||||
| Net income per share, basic | $ | 1.48 | $ | 1.07 | |||||
| Net income per share, diluted | $ | 1.44 | $ | 1.03 | |||||
| Shares used in computing net income per share, basic | 37,284,946 | 36,427,263 | |||||||
| Shares used in computing net income per share, diluted | 38,472,013 | 37,979,448 | |||||||
| SHOCKWAVE MEDICAL, INC. | |||||||||
| Reconciliation of GAAP Net Income to Adjusted EBITDA | |||||||||
| (Unaudited) | |||||||||
| (in thousands) | |||||||||
| Three Months Ended | |||||||||
| March 31, | |||||||||
| 2024 | 2023 | ||||||||
| GAAP Net Income | $ | 55,346 | $ | 39,125 | |||||
| Non-GAAP Adjustments | |||||||||
| Income tax (benefit) provision | (5,347 | ) | 1,612 | ||||||
| Other expense (income), net | 2,496 | (642 | ) | ||||||
| Interest expense | 2,943 | 636 | |||||||
| Interest income | (12,318 | ) | (1,740 | ) | |||||
| (Income) loss from equity method investment | (713 | ) | 823 | ||||||
| Depreciation and amortization | 3,109 | 1,708 | |||||||
| Stock-based compensation expense | 22,937 | 15,967 | |||||||
| Adjusted EBITDA | $ | 68,453 | $ | 57,489 | |||||
Cover |
May 06, 2024 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | May 06, 2024 |
| Entity File Number | 001-38829 |
| Entity Registrant Name | Shockwave Medical, Inc. |
| Entity Central Index Key | 0001642545 |
| Entity Tax Identification Number | 27-0494101 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 5403 Betsy Ross Drive |
| Entity Address, City or Town | Santa Clara |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 95054 |
| City Area Code | 510 |
| Local Phone Number | 279-4262 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common stock, par value $0.001 per share |
| Trading Symbol | SWAV |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
7F\+8Q,DV88AA>
MW0$H[N'?XU5+/5-R+;*P.9FXYG2"H=5]@>+&_CW:3&H#[_+?(C]>?[CBH.MU
M,3^F=:^@N,67JSB![\7C*+A EWH82-T9*&[K'R78)IG%,L-:0XN(?SDX"_R>
MCQ'5O8'BIOZBA#$\@\2D:9'M_4TW4N%";8V=ULV XAX^EXD(A1'9BCQ >2O!
MDD8>7*65I^X"%#?MF>)G(:2'P_NU^_Z"3R#X4ORT7!Y9/UROC